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Introduction 
 
One of the key pathological hallmarks of Alz-
heimer’s disease (AD) is the accumulation of 
amyloid β peptide (Aβ) which can be detected in 
the extracellular space, vasculature and within 
neurons.  Intraneuronal accumulation of Aβ is 
suggested to be one of the earliest pathological 
events and has been shown to be associated 
with cognitive deficits and neurodegeneration 
(see [1] for review). Vascular risk factors are 
implicated in the aetiology of AD and hyperten-
sion in mid-life, in particular, they are associ-
ated with AD and cognitive decline (reviews [2-
5])  In addition to epidemiological studies,  neu-
ropathological studies have also indicated that 
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Abstract:  Background: Reducing the excessive accumulation of amyloid β-protein (Aβ) in Alzheimer's disease (AD) is a 
key objective of most AD therapies. Several studies suggest that pharmacological inhibition of angiotensin-converting 
enzyme (ACE) or its by-product angiotensin II may delay onset or progression of dementia and it has been suggested 
that this occurs via regulation of Aβ. Intraneuronal oligomeric accumulation of Aβ is postulated to be one of the earli-
est pathological events. Thus this study investigated the effect of an ACE-inhibitor, captopril, and two angiotensin II 
receptor blockers (ARBs), eprosartan and valsartan, on intraneuronal Aβ pathology and oligomeric Aβ levels in a triple 
transgenic (3xTGAD) mouse model of AD. Methods: Male, adult (3-4 month old)  3xTgAD mice (n=39) were randomly 
assigned to 4 treatment groups: valsartan (0.17g/l), eprosartan (0.8g/l), captopril (5g/l) or normal drinking water and 
the drugs given ad libitum for 2 months. Mean arterial blood pressure (MABP) was measured at baseline, at 2 weeks 
and at 2 months when the mice were sacrificed and the brains hemisected for analysis. One hemisphere was proc-
essed for Aβ and amyloid precursor protein (APP) immunohistochemistry and the other for biochemical measurement 
of oligomeric Aβ and APP. ACE activity was measured in the brain and kidney. Results: MABP was significantly re-
duced at 2 weeks and 2 months in the ACE-I group (p=0.0006) but was unaltered in the ARB groups compared to 
vehicle.  Neither ACE-I nor ARB treatment altered Aβ and APP immunolabelling or the level of Aβ or APP in brain tissue 
homogenates. Similarly neither ACE-I nor ARB treatment altered ACE activity in either brain or kidney compared to 
control tissue. Conclusions: ACE-I or ARB administration over 2 months did not affect APP levels or either intraneu-
ronal Aβ or oligomeric Aβ levels in 3xTGAD mice. While ARBs did not alter MABP, captopril did mediate reductions in 
MABP in the 3xTGAD mice which appeared to be independent of ACE activity. Further studies are needed to examine 
the effects of these drugs over a longer term and in older mice (i.e. when AD-like changes are more pronounced). 
 
Keywords: Angiotensin converting enzyme inhibitor, angiotensin-II receptor blocker, triple transgenic mouse model, 
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there is a link between hypertension and risk of 
AD, via the demonstration that hypertension 
increases accumulation of Aβ .  
 
However, whilst several studies have indicated 
that hypertension may play an important role in 
development of cognitive decline or AD there is 
conflicting evidence from the study of anti-
hypertensives. In some [6-12], but not all [13-
14]), observational studies to date, antihyper-
tensive drugs slowed the incidence or rate of 
cognitive decline in patients with mild cognitive 
impairment (MCI) or AD. The disparities in these 
studies may reflect methodological limitations 
such as small sample size and low statistical 
power [15-16]. Of the most promising findings, 
have been those associated with the use of the 
anti-hypertensives, angiotensin converting en-
zyme inhibitors (ACE-Is) or angiotensin receptor 
blockers (ARBs). ARBs, are associated with a 
lower incidence and rate of progression of AD 
and dementia than that seen in patients given 
ACE-Is or other anti-hypertensive medication [8]. 
Moreover, ARBs have also been reported to en-
hance cognitive function in normal people [17]. 
ARBs are newer, more expensive and less 
widely used than ACE-Is and as a result, pre-
clinical and epidemiological data on their use 
and relevance in experimental models of de-
mentia and in human subjects is currently lim-
ited. Nonetheless a recent trial involving 25,475 
patients demonstrated a significant improve-
ment in the mini-mental state examination 
score over a 6-month period of treatment with 
eprosartan [18]. Losartan also improved per-
formance of immediate and delayed memory 
tasks in very elderly hypertensive patients [19]. 
These findings have prompted calls for further 
study of the utility of these drugs in preserving 
cognition or at least slowing the progression of 
dementia [8, 12, 20-22].   
 
The mechanism by which anti-hypertensives 
may be beneficial is unclear and may be related 
to direct effects on lowering blood pressure and 
by improving blood flow, and there is evidence 
that  they might have direct actions on Aβ accu-
mulation. However these latter links are con-
founded by several in vitro, in vivo and ex vivo 
laboratory studies that demonstrate ACE pro-
motes the degradation of Aβ [23-28]  whereas 
ACE-I can result in an increase or  accumulation 
of  Aβ [24, 27]. These findings raise concern 
that long term use of ACE-Is may exacerbate 
accumulation of Aβ and perhaps accelerate 
cognitive decline [21, 27-29]. To date, there has 
been a lack of investigation of the long-term 
effects of ACE-I although one in vivo study has 
indicated that the ACE-I , captopril,  has no ef-
fect on Aβ  deposition in a mutant mouse model 
of AD [26].   
 
The major vasotonic product of ACE activity, 
angiotensin II (AngII), is prevented from binding 
to its receptors by ARBs without altering ACE 
activity. ARB treatment has been shown to im-
prove cognitive performance and reduce Aβ 
pathology in in vivo models of AD [27, 30-31] 
and while in animal studies valsartan reduced 
Aβ accumulation and improved cognitive per-
formance in Tg2576 mice [27], telmisartan im-
proved cognitive function in mice given in-
tracerebral injections of Aβ1-40 [30], and olme-
sartan improved cognitive and cerebrovascular 
function in mice that were given intracerebral 
injections of Aβ1-40 (actions independent of the 
antihypertensive activity of the drug) and re-
duced cerebrovascular dysfunction in young 
APP23 mice [32]. Thus, ARBs may be more 
beneficial as a treatment strategy, acting to re-
duce Aβ load as compared to ACE-I that may 
increase accumulation of Aβ.  
 
In view of the links between anti-hypertensives 
and Aβ accumulation and potential disparities 
between their modes of action, the present 
study sought to compare the effects of an ACE-I 
(captopril) and ARBs (valsartan, eprosartan) on 
Aβ accumulation. Since recent evidence empha-
sises the importance of intraneuronal and oli-
gomeric Aβ as a precursor of degeneration and 
cognitive decline, we examined the effects of 
these compounds in a 3xTGAD mouse model of 
AD at an age in which intraneuronal Aβ is pre-
sent but extracellular amyloid deposition ab-
sent.  The accumulation of intraneuronal Aβ is 
associated with cognitive deficits in this model 
[34] and thus alterations in intraneuronal Aβ as 
a result of ACE-I or ARBs may be indicative of 
cognitive alterations.  
 
Methods 
 
Animals 
 
Adult (3-4 months old), male triple transgenic 
(3xTGAD; PS1m146vKI; Thy1.2-APPswe; Thy1.2-
tauP301L) mice [33] were used in this study. The 
animals were group-housed under a 12-hour 
light/dark cycle with access to food and water 
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ad libitum until the day of the experiment. Room 
temperature in the animal house was main-
tained at approximately 21 ± 2°C. Mice (n=39 
total; all groups n=10, except Valsartan n=9) 
were randomly assigned to a treatment group 
prior to study commencement. Researchers 
were blinded to drug treatment at all times. All 
animal procedures were performed according to 
the Animal Scientific Procedures Act of 1986 
under license from the United Kingdom Home 
Office. 
 
Drug treatment 
 
The drugs were administered in drinking water 
to avoid the stress of repeated injections over a 
2-month period and to mimic the human situa-
tion. The ARBs used were eprosartan (0.8g/l) 
and valsartan (0.17g/l) and the ACE-I was cap-
topril (5g/l) and a control group received drink-
ing water only. The doses selected were in-
formed by pilot studies on C57Bl/6J mice in 
which each of the drugs was administered in 
several different concentrations (captopril 2, 5 
and 10g/l; eprosartan 0.3, 0.6 and 0.9g/l, val-
sartan 0.05 and 0.2g/l) and mean arterial blood 
pressure (MABP) monitored over 28 days. None 
of the final doses selected had any significant 
effect upon MABP (Figure 1) and so hypotension 
and vascular insufficiency were removed as 
potential confounding factors. The dose of ep-
rosartan (eprosartan monosodium salt, Solvay 
pharmaceuticals) equates to ~13mg/kg in hu-
mans, which is the maximum that may be pre-
scribed in human patients (www.bnf.org). That 
of valsartan (valsartan monosodium salt, LGM 
Pharma) equates to approximately twice the 
average dose administered to human patients, 
and half the maximum prescribable dose and is 
comparable to previous studies in which doses 
of 10–40mg/kg inhibited Aβ accumulation in 
vitro and in vivo [27]. The dose of captopril 
(LGM Pharma) was approximately 30 times 
greater than the maximum dose normally pre-
scribed for human patients.  
 
The drugs used in this study are all weak acids, 
and are thus well absorbed in their non-ionised 
form from the stomach. To prepare the ARBs for 
administration in drinking water, they were first 
dissolved in 3-4ml sterile distilled water (dH2O) 
plus a small amount of 5M sodium hydroxide 
(NaOH) titrated to the amount of drug being 
used. This solution was vigorously vortexed until 
the drug was completely dissolved, then added 
to the appropriate volume of sterile dH2O with 
continuous stirring. The final solution was fur-
ther neutralized to pH 7.0 by addition of 5M 
NaOH. Captopril was prepared by adding the 
drug to the appropriate volume of sterile dH2O 
and neutralizing to pH 7.0 by the addition of 5M 
NaOH with continuous stirring. All drinking solu-
tions were freshly prepared twice each week, 
the containers wrapped in aluminium foil to 
avoid potential photochemical changes and 
kept at room temperature to avoid potential 
precipitation from solution. Fluid consumption 
was monitored twice weekly throughout the 
study. 
 
Blood pressure measurement 
 
MABP was monitored non-invasively with a tail 
sphygmomanometer (Panlab, LE5002). MABP 
was measured at baseline, prior to the start of 
drug delivery, 2wk after drug delivery had begun 
and immediately before termination of the ex-
periment (at 2mo). Ten measurements were 
taken each day and the average for each mouse 
determined from the last 5 measurements. 
Figure 1. Effect of ACE-inhibitor and ARB upon MABP 
in C57Bl6/J mice.  The data illustrate the range and 
maximal drug doses of, a) Captopril and b) Eprosar-
tan and Valsartan, which were well tolerated but did 
not alter mean arterial blood pressure (MABP) over a 
period of 28 days. 
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Mice were habituated to the procedure for 5d 
before each measurement day to minimise 
stress and anxiety. Visual inspection of the 
pulse trace was carried out to ensure that 
movement artefacts had not occurred during 
the measurement; if these were detected the 
measurement was discarded. Any measurement 
that coincided with a heart rate of over 700 
beats per minute (bpm) was discarded as this is 
indicative of excessive stress in the animal [34].   
 
Tissue preparation 
 
After 2mo the animals were anaesthetised with 
isoflurane and sacrificed by transcardial perfu-
sion with cold saline. Brains were harvested and 
hemisected midsagittally. One hemisphere was 
snap frozen in liquid nitrogen for biochemical 
analyses, the other fixed in 4% paraformalde-
hyde for 48h for histology and immunohisto-
chemistry. From each mouse, a kidney was iso-
lated and snap-frozen for subsequent analysis 
of ACE activity. 
 
ACE activity assay 
 
ACE activity was determined using the fluoro-
genic substrate (Abz-FRK(Dnp)-P; BIOMOL). 
Brain tissue or kidney was homogenised in lysis 
buffer with Biospec 2.3mm Zirconia/Silica 
beads using a PrecellyS automatic homogeniser 
for 2 x 15s at 6000 rpm. The homogenates 
were then spun for 15min at 13000 rpm in a 
centrifuge refrigerated to 4°C. The protein con-
centration of each sample was measured using 
Total Protein kit (Sigma). This value was used to 
calculate the volume of each sample to be used 
subsequently in the ACE activity assay, in which 
the protein concentration in each sample was 
standardised to 50ug/ml total protein. Samples 
were diluted in HEPES buffer (595mg in 50ml 
dH2O; pH 6.5) and 50µl of each sample was 
incubated for 18h at 26°C with Abz-FRK(Dnp)-P. 
Triplicates of each sample were incubated with 
10ug (100mM) captopril (Biomol International, 
Exeter, UK) which inhibits the reaction by over 
90% [35]. The fluorescence of Abz-FRK(Dnp)-P 
was measured with excitation at 320nm and 
emission at 405nm in a 96-well plate using a 
FLUOstar OPTIMA plate reader, and the differ-
ence between captopril-inhibited and non-
inhibited samples used to calculate ACE activity. 
ACE activity was expressed in arbitrary units. 
Treatment groups were compared by 1-way 
ANOVA, with significance set at P<0.05. 
Immunohistochemistry 
 
The fixed brain tissue was sliced coronally at 
3mm intervals and the slices embedded in par-
affin wax. Sections 6µm in thickness were col-
lected onto Superfrost slides and dried on a 
hotplate. The sections were dewaxed and hy-
drated through a series of graded alcohols and 
washed in phosphate-buffered saline (PBS). 
Endogenous peroxidase activity was blocked by 
incubation in 3% hydrogen peroxide in methanol 
for 30min. For labelling of Aβ, antigen retrieval 
was carried out by covering the sections in 80% 
formic acid for 10min. Antigen retrieval for APP 
was carried out by boiling the sections in citric 
acid buffer twice for 5min. Sections were 
blocked in normal horse serum for 1h at room 
temperature then incubated overnight with the 
anti-Aβ antibody 4G8 (Millipore) or anti-APP 
(Chemicon Clone 22C11), both diluted 1:1000, 
at 4oC. Sections were washed in PBS, incubated 
with anti-mouse biotinylated secondary antibody 
(1:100) for 1h at room temperature, washed 
and bound antibody visualised by the avidin/
biotin method (ABC Elite kit, Vector laboratories) 
with diaminobenzidine (DAB) as the chromogen. 
 
In 3xTGAD mice, aged 5-6mo, Aβ is detectable 
intraneuronally but at this age there is no ex-
tracellular deposition of Aβ. To quantify intra-
neuronal Aβ and APP, three non-overlapping 
images of the CA1 field of the hippocampus and 
three from somatosensory cortex were captured 
from each immunostained section [x40 magnifi-
cation] and the percentage area of section la-
belled for Aβ or APP was determined using Im-
ageJ software. Four separate sets of measure-
ments were made for each animal in each re-
gion of interest and the mean for each region 
calculated. Treatment groups were compared by 
1-way ANOVA with significance set at P<0.05. 
 
Tissue homogenisation 
 
Brains were homogenized in 10 volumes 
(wt:vol) of tissue homogenization buffer (THB; 
250mM sucrose, 20mM Tris base, 1mM EDTA, 
1mM EGTA). The homogenate was mixed 1:1 
with 0.4% diethanolamine buffer (DEA; 200μl 
DEA, 1ml 5M NaCl, ddH2O to 50ml) and centri-
fuged at 135,000xg at 4°C for 1h. The super-
natant was saved as the soluble fraction. The 
insoluble pellet was re-suspended in cold formic 
acid, briefly sonicated and spun at 135,000xg 
at 4°C for 1h. The resulting supernatant was 
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diluted (210μl:4ml of formic acid neutralization 
buffer, comprising 50.57g Tris base, 35.5g 
Na2HPO4, 2.5ml 10% NaN3, H2O to 500ml) and 
saved as the insoluble fraction. 
 
Quantification of full length APP  
 
Soluble proteins were extracted from brain tis-
sue as described. 10μg was loaded onto a Tris-
bis 4-12% gel and the proteins separated by 
electrophoresis at 150V for 1.5h. Each of 3 gels 
contained samples from the control group and 
samples from an individual drug treatment 
group, to avoid inter-gel comparisons. Proteins 
were transferred to a PVDF membrane and 
probed with MAB348 (Millipore) to detect full 
length APP and GAPDH antibody (Abcam) to 
assess protein loading. Bands were visualised 
with the appropriate Odyssey infrared secondary 
antibodies (IRDye; LiCor) and band intensity 
measured using Odyssey Infrared Imaging Sys-
tem (LiCor). APP measurements were adjusted 
for (the slight) variations in GAPDH band inten-
sity.  Each treatment group was compared to 
control using Student’s t test with significance 
set at P>0.05 and the mean for control and 
treatment group was calculated for each mem-
brane and visualised in a histogram. 
 
Levels of oligomeric Aβ 
 
The levels of oligomeric Aβ were measured in 
the soluble fraction by dot blot analysis with the 
A11 antibody. 2µg of soluble protein was loaded 
in duplicate into the 96-well manifold of the bio-
dot microfiltration apparatus (Bio-rad) below 
which a pre-wetted nitrocellulose membrane 
had been placed. Samples were rapidly filtered 
through the membrane, which was removed 
and placed into blocking buffer (Odyssey) for 1h 
at room temperature with constant agitation. 
Membranes were incubated overnight with A11 
antibody at 4°C with constant agitation. After 
they had been washed, membranes were incu-
bated with infrared secondary antibodies 
(IRDye; LiCor) for 45min at room temperature 
and scanned using Odyssey infrared Imaging 
System (LiCor). Relative optical density was 
measured and the mean for each sample calcu-
lated. Treatment groups were compared by 1-
way ANOVA with Dunn’s post hoc multiple com-
parison test and significance set at P<0.05. 
 
Statistical analysis 
 
Statistical tests were performed with GraphPad 
Prism, version 5 (GraphPad Software, La Jolla, 
CA). Changes in MABP were analysed by re-
peated measures ANOVA. ACE activity and Aβ 
and APP immunolabelling were analysed by one-
way ANOVA with Dunn's test for post hoc com-
parisons between experimental and control 
groups. Statistical significance was set at 
P<0.05 for all analyses. 
Figure 2. Mean arterial 
blood pressure at base-
line and following 2 
weeks and 2 months of 
treatment with either 
(a) drinking water only 
(control), (b) captopril  
(5g/litre), (c) eprosar-
tan (0.8g/litre) or (d) 
valsartan  (0.17g/litre). 
* indicates significantly 
different from baseline; 
data were analysed 
using repeated meas-
ures 1-way ANOVA with 
Dunn's post-hoc for 
multiple comparisons. 
Significance was set at 
p<0.05. 
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Results 
 
Mean arterial blood pres-
sure 
 
Mean arterial blood pres-
sure (MABP) measure-
ments at 2wk and 2mo 
after starting treatment 
were compared with that 
at baseline (Figure 2). 
There was no significant 
change in MABP in con-
trols, mice given eprosar-
tan (0.8g/l of drinking 
water) or valsartan 
(0.17g/l). However capto-
pril (5g/l) induced a sig-
nificant reduction in 
MABP in 3xTGAD mice at 
2wk and 2mo after the 
commencement of treat-
ment (p=0.0006, Figure 
2). 
 
ACE activity 
 
ACE activity was as-
sessed in homogenates 
of both brain and kidney 
Figure 3. ACE inhibitor and ARB treatment does not affect ACE activity in the 3xTGAD mouse.  3xTGAD mice were 
treated with captopril (5g/litre), eprosartan (0.8g/litre), valsartan (0.17g/litre) and drinking water for 2 months.  ACE 
activity was determined in brain (a) and kidney (b) tissue using a fluorogenic substrate for Angiotensin converting 
enzyme; ACE activity is expressed in arbitrary units. 
Figure 4. ACE inhibitor and ARB treatment does not affect intraneuronal levels of amyloid or amyloid precursor pro-
tein (APP)  in the 3xTGAD mouse.  3xTGAD mice were treated with captopril (5g/litre), eprosartan (0.8g/litre), valsar-
tan (0.17g/litre) and drinking water for 2 months. Brain sections were stained for amyloid (a,c)  and APP (b,d) and 
visualised in hippocampus CA1 (a, b) and somatosenory cortex (c, d). The percentage area stained was determined 
using computer-assisted image analysis (ImageJ). 
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in all groups to determine the effects of treat-
ment on central and peripheral ACE activity 
(Figure 3). ACE activity tended to be higher in 
the brain than the kidney. No significant effect 
of drug treatment on ACE activity was detected 
in either brain or kidney, this despite the clear 
physiological effect of captopril on blood pres-
sure. 
 
Immunohistochemistry 
 
Intraneuronal Aβ and APP were detected in the 
hippocampus and cortex in the control treated 
group and drug-treated groups (Figure 4). No 
extracellular Aβ deposition was seen in any of 
the groups. Quantification of intraneuronal Aβ 
immunolabelling revealed only slight variation 
between the groups in the area of the CA1 field 
of the hippocampus which was immunopositive 
for Aβ, and the differences were not significant. 
There was greater variation in the cortex, where 
the labelling between groups varied by as much 
as 50%, being lowest in captopril-treated mice 
and highest in those given valsartan, but once 
again these differences did not reach statistical 
significance. APP labelling varied only slightly 
(and not significantly) between the groups in 
both the hippocampus and the cortex. 
 
Levels of APP and oligomeric Aβ 
 
The total protein levels of full-length APP were 
determined in Western blots prepared from 
brain tissue homogenates of all control and 
drug-treated mice. The protein levels of APP did 
not differ signficantly between any of the drug 
exposure groups and controls (Figure 5). 
 
Oligomeric Aβ could be detected by the antibody 
A11 as shown in Western blots of the soluble 
Figure 5. ACE inhibitor and ARB treatment does not affect the protein levels of full-length amyloid precursor protein 
(APP) in the 3xTGAD mouse.  3xTGAD mice were treated with captopril (5g/litre), eprosartan (0.8g/litre), valsartan 
(0.17g/litre) and drinking water for 2 months.  Soluble proteins were isolated from brain tissue samples as described 
and expression of APP was examined in 10µg of protein by western blot analysis. Each drug treatment group was 
randomly loaded onto a single gel alongside samples from the control group [(a) captopril, (c) eprosartan and (e) val-
sartan]; representative images are shown from each treatment group [(b) captopril, (d) eprosartan and (f) valsartan]. 
The membranes were probed with anti-APP antibody and GAPDH, and the relative intensity normalised to GAPDH for 
each gel. Data were analysed using Student's t test with significance set at P>0.05. 
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and not insoluble fraction in both 3xTGAD mice 
and AD patients (Figure 6). Subsequently the 
levels of total oligomeric Aβ species were com-
pared between the control and drug-treated 
groups by  dot blot analysis. There were no sig-
nificant differences in the levels of oligomeric 
Aβ between the controls and any of the treat-
ment groups. 
 
Discussion 
 
Reduction in blood pressure and improvements 
in cerebral blood flow have been the most com-
monly suggested mechanisms to explain obser-
vations that anti-hypertensive treatments may 
be beneficial in AD, although there has been 
some suggestion of a more direct action on Aβ 
accumulation. However, conflicting indications 
from pre-clinical studies suggest that ACE-Is, by 
inhibiting ACE, may have an adverse effect on 
Aβ [23, 25-26, 36-37]. This study investigated 
the potential impact of ACE-Is and ARBs on in-
traneuronal Aβ and oligomeric levels of Aβ in 
the 3xTGAD mouse model of AD.  
 
Present findings in relation to previous research 
 
Intraneuronal Aβ and APP were detected in all 
groups of mice, consistent with other reports on 
animals of the same age (5-6mo) in this trans-
genic model [33] and at this age there was no 
evidence of extracellular Aβ deposition  in any of 
the groups at 6mo. Thus we were able to ad-
dress whether anti-hypertensives had an effect 
on early intraneuronal and oligomeric Aβ. Our 
data robustly demonstrate that treatment over 
2 months with an ACE-I, captopril, or two ARBs, 
valsartan and eprosartan; have no significant 
effect on the levels of soluble APP (sAPP), intra-
neuronal oligomeric Aβ or oligomeric Aβ levels. 
These observations partly agree with those of 
Hemming and colleagues [38] who also found 
no differences in levels of soluble and insoluble 
Aβ (total), Aβ40 and Aβ42 in captopril or losar-
tan treated 3xTGAD mice as well as in an older 
captopril treated J20 transgenic mice. In con-
trast, perindopril, another reported brain-
penetrating ACE-I, improved cognitive deficits in 
Aβ25-35-injected mice [39] and Aβ1-40-injected 
Sprague Dawley rats [24]. In both of these stud-
ies reductions in brain ACE activity were also 
reported after short treatment periods but the 
reductions did not approach the abolition of ACE 
activity reported by Hemming and colleagues 
[38]. 
 
In other studies using ARBs, Wang and col-
leagues found diminished Aβ pathology in 
Tg2576 mice treated with valsartan for 5mo 
which coincided with better cognitive perform-
ance [27]. Takeda and colleagues also showed 
that a short course of olmesartan (4-5 weeks) 
ameliorated cerebrovascular dysfunction and 
oxidative stress in young APP23 mice but did 
not coincide with any changes to soluble or in-
soluble levels of Aβ1-40 and Aβ1-42. Similarly 
Figure 6. ACE-inhibitor and ARB treatment does not affect oligomeric Aβ species (A11) in young 3xTGAD mice treated 
with captopril (5g/litre), eprosartan (0.8g/litre), valsartan (0.17g/litre) and drinking water for 2 months. Levels of 
oligomeric Aβ were assessed by dot blot but there was no statistical difference in the levels of oligomeric Aβ deter-
mined between the drug-treated and control groups (a) . Western blot analysis of Aβ as detected by A11 antibody 
showing presence of multiple oligomeric species in soluble (S) fractions, but not insoluble (IN) fractions, prepared 
from brain homogenates of Alzheimer disease (AD) cases and 3xTGAD mice (b).  
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effects were also found by the same group in an 
Aβ1-40-injected mouse model [32].  
 
Levels of brain and kidney ACE activity were 
comparable in this study in contrast to the find-
ings of Hemming and colleagues [38] who used 
slightly younger (3mo) 3xTGAD mice which were 
treated for 28d with 2g/l of captopril and a dif-
ferent ARB (losartan at 0.6g/l). While the brain 
ACE activity data were similar between the stud-
ies, in that no differences were found across 
groups of animals, our kidney measurements 
differed in not showing a detectable reduction 
in ACE activity in captopril treated mice, despite 
a clear hypotensive effect. [38]. The ARBs used 
in both studies had no effects on ACE activity, 
although the losartan used by Hemming et al 
showed a modest reduction in ACE activity 
which we did not find for either valsartan or ep-
rosartan. 
 
In contrast to other studies we attempted to 
disentangle possible anti-hypertensive and 
other unknown drug specific effects on the dis-
ease phenotype by selecting from pilot studies 
the maximal drug doses that were well tolerated 
but did not alter mean arterial blood pressure 
(MABP) in otherwise normotensive wild-type 
mice. However the same doses applied to 
3xTGAD mice evoked a significant progressive 
and sustained reduction (19%) in MABP 
(p=0.0006) in the captopril treated group al-
though not in the valsartan or eprosartan 
groups. No blood pressure measurements were 
reported by Hemming and colleagues for the 
3xTGAD mice [38]. The absence of any MABP-
lowering effects from valsartan in our 3xTGADs 
is consistent with the observations of Wang et al 
on Tg2576 mice, in which valsartan (10 or 
40mg/kg/d) ameliorated Aβ pathology and im-
proved spatial memory deficits [27].  
 
Possible explanations for the differences 
 
Noteworthy in the current study was the lack of  
extracellular Aβ deposition in contrast to some 
reports in 3xTGAD mice in the age-range studied 
[33], and the lack of captopril-mediated reduc-
tions in ACE activity in the kidney [38].  Studies 
of other ACE-Is in other murine [39] and rodent 
[24] models documented reductions in brain 
ACE activity which neither this nor another study 
[38] of 3xTGAD found.  The studies on ACE in 
3xTGAD mice differed in the methods used. 
Hemming and colleagues [38] administered 2g/
l of captopril for 28d in contrast to our 5g/l for 
2mo.  ACE activity was also measured differ-
ently in the studies. While both studies used 
detergent-free homogenates Hemming and col-
leagues (personal communication) used man-
ual homogenisation whereas we used rapid, 
high-throughput machine-based homogenisa-
tion with ceramic beads, which may have re-
sulted in differing yields in the final proportions 
of membrane-bound and soluble forms of ACE 
that were represented in the resulting homoge-
nates. This could be particularly relevant to the 
kidney which is more fibrous and resilient. 
Moreover, the ACE substrates used also dif-
fered: Hemming and colleagues used a hippuryl-
L-histidyl-L-leucine (His-His-Leu) ACE substrate 
in contrast to our use of the ACE-specific fluoro-
genic peptide substrate Abz-FRK(Dnp)-P as in 
previous studies [35, 40]. However the results 
produced by the two substrates were reported 
to be closely correlated (r2=0.90) in parallel 
measurements of plasma ACE activity [41] al-
though the HHL assay has been shown possibly 
to underestimate ACE activity and this may well 
be a tissue-specific effect [42]. These methodo-
logical differences and the differences in the 
ages of the animals at the time of assay may 
have been relevant. In addition, the Hemming et 
al 3xTGAD mouse had extracellular Aβ pathol-
ogy which ours did not.  
 
The preparation of the captopril drug could also 
have been a contributing factor to the lack of 
apparent kidney ACE activity disparity. However 
that significant and sustained reduction in 
MABP was observed for the captopril-treated 
mice, consistent with other studies using lower 
doses of captopril (2g/l) [38] suggests similar 
bioavailability and makes this an unlikely factor. 
The absence of reported blood pressure meas-
urement data by Hemming and colleagues lim-
its comparisons on this point. Animal strain dif-
ferences, as well as drug-specific differences, 
are likely to be important in these observations, 
particularly as the same dose of captopril had 
no effect on MABP in our pilot experiments on 
C57Bl6/J mice and neither eprosartan nor val-
sartan altered MABP in the 3xTGAD mice.  
 
Limitations of the present study 
 
In this study a  high dose of captopril was used: 
30 times greater than the maximum dose nor-
mally prescribed for human patients, although 
only 2.5 fold higher than that used by Hemming 
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and colleagues in 3xTGAD [38]. Although in our 
pilot studies this dose did not affect blood pres-
sure in C57Bl6/J mice, it is clear that optimisa-
tion in 3xTGAD would have been advisable. An-
other limitation of the present study was that we 
did not assess cognitive function; Takeda et al 
[32] found that the ARB olmesartan improved 
spatial learning in APP23 mice despite a lack of 
change in Aβ level. In addition, the lack of 
change in brain ACE activity after systemic cap-
topril administration does raise questions re-
garding the alleged BBB penetrability of capto-
pril [10, 12]. The brain penetrating ACE-I perin-
dopril was shown to reduce brain ACE activity in 
another study [39].  Finally it is worth consider-
ing that we focussed our study on the measure-
ment of intraneuronal oligomeric Aβ and levels 
but arguably anti-hypertensives may exert bene-
ficial effects via other mechanisms such as by 
improving cerebral blood flow and haemody-
namics which would impact positively on vascu-
lar integrity. 
 
Implications of the present findings 
 
We found no evidence that ACE-Is had a detri-
mental effect on neuronal or total oligomeric Aβ 
or precipitated extracellular Aβ pathology in the 
3xTGAD mice studied. This would suggest that if 
any of these compounds did exert an action on 
Aβ that at this age the Aβ was able to be me-
tabolised or cleared efficiently. Data from other 
similar studies provide reassurance that ACE-Is 
may not increase AD pathology [38] and may 
improve cognitive and cerebrovascular function 
in people[27, 30-32].  
 
Conclusions, including plans for future studies 
 
The present study was limited to a short–term 
treatment strategy with different anti-
hypertensives in a 3xTGAD model but longer-
term treatments should be assessed to define 
in a number of models both familial and spo-
radic. Future studies should assess blood pres-
sure, cerebrovascular function, cognitive per-
formance and ACE activity in different cellular 
and tissue compartments, as well as a range of 
markers of AD pathology.  
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